Main focus: Base editing for the treatment of genetic diseases and cancer
Company stage: Preclinical
Diseases: Sickle cell disease, beta-thalassemia, acute lymphoblastic leukemia (ALL), alpha-1 antitrypsin deficiency, glycogen storage disorder-1, Stargardt disease
Genome editing tool: Cytosine base editor, adenine base editor, Prime editing
Funding stage: Public (NASDAQ:BEAM)
Location: Cambridge, MA, USA
Partners: Prime Medicine, Apellis Pharmaceuticals, Verve Therapeutics, Bio Palette
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
Their most advanced programme is in IND enabling studies for sicle cell anemia.